rss
Br J Ophthalmol 1995;79:439-441 doi:10.1136/bjo.79.5.439
  • Research Article

Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium.

  1. J Cano-Parra,
  2. M Diaz-Llopis,
  3. M J Maldonado,
  4. E Vila and
  5. J L Menezo
  1. Department of Ophthalmology, La Fe University Hospital, Valencia, Spain.

      Abstract

      AIMS--A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted. METHODS--A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months). RESULTS--Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group. CONCLUSION--Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.

      This Article

      Services

      1. Request permissions

      Responses

      1. Submit a response
      2. No responses published

      Social bookmarking

      Register for free content


      Free sample
      This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
      View free sample issue >>

      Free archive
      The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
      Register to access the free archive >>

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.